BeiGene assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of BeiGene (BGNE) with an Overweight rating and $300 price target The firm sees BeiGene’s Brukinsa continuing to gain share within the Bruton Tyrosine Kinase inhibitors market and notes that the company also has two complementary drug candidates entering Phase 3 clinical trials in the first half of 2025, which it says will enhance the company’s “leading position” in the treatment of B-cell malignancies.